The city of Miami, Florida, currently has 52 active clinical trials seeking participants for Lung Cancer research studies.
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
NCT05657873
Recruiting
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida
Conditions: Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Local Institution - Unk076, Miami, Florida
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Study Site, Miami, Florida
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815
Recruiting
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Miami, Miami, Florida
Conditions: Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida +1 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
NCT05653882
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: University of Miami, Miami, Florida
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Register for Updates
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
NCT05636618
Recruiting
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/28/2025
Locations: Biogenix Molecular, Miami, Florida
Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Tumor Carcinoid, Carcinoid Tumor of GI System, Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Small-cell Lung Cancer
Register for Updates
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174
Recruiting
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/04/2024
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers
NCT06626243
Recruiting
The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy. There are no risks for the patients, as this is a retrospective data collection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Baptist Health South Florida, Miami, Florida
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
NCT06426628
Recruiting
The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? * Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is c... Read More
Gender:
ALL
Ages:
Between 29 years and 85 years
Trial Updated:
11/12/2024
Locations: Bruce W. Carter Miami VA Medical Center, Miami, Florida
Conditions: Pulmonary Nodule, Solitary, Lung Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: USA029 University of Miami Sylvester Comprehensive Cancer Center 1550 NW 10th Avenue 33173 Miami FL Ikpeazu Chukwuemeka N, Miami, Florida
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates